Jung+ Longevity is a technology company.
Jung+ Longevity has raised $570K across 1 funding round.
Jung+ Longevity has raised $570K in total across 1 funding round.
Jung+ Longevity has raised $570K in total across 1 funding round.
Jung+ Longevity's investors include Healthspan Capital.
Jung+ is a consumer longevity company founded in Oxford that builds the Total Longevity System™, a precision-engineered program of supplements, lifestyle protocols, and biomarker testing to target the 12 hallmarks of aging, slow biological aging, and extend healthspan.[1][3][6] It serves everyday consumers seeking affordable access to elite longevity science—priced from around $120/month—solving the problem of high-cost clinic programs ($100,000+ annually) by offering a DTC, self-guided three-step system: a master formula (AM/PM for circadian alignment), targeted boosters (e.g., skin renewal, fasting support), and ongoing scientific updates.[1][4][5] After five years of R&D and a private beta with 10,000 users, Jung+ launched publicly in 2024, democratizing interventions like NAD+ boosting and senescent cell clearance backed by 400+ peer-reviewed studies.[1][4]
Jung+ was founded by Simon Sakhai, a University of Oxford alumnus and former President (now Chairman) of the Oxford Society of Ageing and Longevity, who assembled a team of global experts including scientists and doctors.[1][4][5] The idea emerged from Sakhai's recognition of a "17-year gap" between longevity discoveries and consumer access, inspired by elite clinics but aimed at the masses—"longevity for the billions, not just the billionaires."[1][5] Key contributors include longevity researcher Pellay, with 11+ years in skin rejuvenation and founding firms like Cell Culture Lab and Bimini Biotech.[5] After five years of R&D, pivotal early traction came via a 10,000-strong private beta community, leading to the 2024 launch of its hero products.[1][4]
Jung+ rides the consumer-driven longevity boom, where demand for anti-aging tech outpaces elite clinics, fueled by rapid science advances (medical knowledge doubling in 73 days by 2020) and consumer adoption of biomarker tracking and senolytics.[3][4][5] Timing is ideal post-2024 launch amid mainstreaming of hallmarks-of-aging research, with market forces like DTC healthtech growth and falling supplement costs enabling scalability.[1][2] It influences the ecosystem by bridging labs to consumers—updating formulas dynamically, empowering functional doctors, and proving longevity products can achieve clinic-level impact affordably, potentially accelerating mass adoption beyond billionaires.[1][4][5]
Jung+ is poised to scale via clinician partnerships and product expansions (e.g., more boosters, advanced testing), capitalizing on trends like AI-personalized longevity and mainstream NAD+ therapies.[1][3] Evolving consumer biotech will shape it—expect integrations with wearables for real-time biomarker tweaks and global trials validating outcomes. Its influence could grow by setting DTC standards, pulling more pharma into accessible healthspan tech and redefining aging as optimizable, tying back to its crusade: elite science for all.[5]
Jung+ Longevity has raised $570K across 1 funding round. Most recently, it raised $570K Seed in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $570K Seed | Healthspan Capital |